Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Quisinostat for Preventing Metastasis after Treatment of High-Risk Uveal Melanoma

Trial Status: active

This phase II trial tests how well quisinostat works in preventing tumor cells from spreading (metastasis) in patients with high-risk uveal (eye) melanoma (UM) who have already received radiation therapy or surgery. It is estimated that up to half of all patients who receive treatment for UM will have their UM return and spread to other parts of their body at 5 or more years post-treatment. There is no curative or effective treatment for metastatic uveal melanoma. Quisinostat is a compound that can block the activity and growth of certain types of tumor cells. Giving quisinostat after radiation therapy or surgery may kill any remaining tumor cells and prevent the disease from spreading in patients with high-risk UM.